Related Experiment Video
Updated: Aug 13, 2026

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
Published on: December 14, 2020
Oral ranitidine and duration of gastric pH >4.0 in infants with persisting reflux symptoms
Silvia Salvatore1, Bruno Hauser, Alessandro Salvatoni
1Clinica Pediatrica di Varese, Università dell'Insubria, Varese, Italy.
Insights
Ranitidine treatment for infant gastro-oesophageal reflux (GOR) may not always be effective. Some infants require better acid suppression or their symptoms may not be acid-related.
Area of Science:
- Pediatric Gastroenterology
- Pharmacology
- Clinical Medicine
Background:
- Ranitidine is frequently used for pathological gastro-oesophageal reflux (GOR) in infants.
- Limited data exist on ranitidine's effect on esophageal acid exposure and gastric acid reduction in this population.
- Non-responsiveness to ranitidine in infants with GOR has been reported.
Purpose of the Study:
- To evaluate esophageal acid exposure in infants with GOR who do not respond to ranitidine.
- To assess the reduction in gastric acid secretion with ranitidine treatment.
- To examine the histology of esophageal biopsies in non-responsive infants.
Main Methods:
- 103 infants with persisting reflux symptoms despite ranitidine treatment were studied.
- A mean ranitidine dose of 9.4 mg/kg/d was administered for at least 2 weeks.
- A 24-hour pH study and esophageal biopsy (in 90/103 infants) were performed.
Main Results:
- Histological esophagitis was found in 23% of infants.
- The esophageal reflux index (RI) was elevated (>5%) in 20% of infants.
- Ranitidine dosage showed a weak correlation with esophageal RI (p=0.05) but not with gastric pH control.
Conclusions:
- Some infants with presumed GOR symptoms do not respond to ranitidine.
- This lack of response may be due to inadequate acid suppression.
- Alternatively, symptoms might not be primarily acid-related in these infants.
Background:
Ranitidine is a drug commonly used in pathological gastro-oesophageal reflux (GOR) in infants. Non-responsiveness has been reported. Data regarding the effect of ranitidine on oesophageal acid exposure and reduction of gastric acid secretion are limited in this age group.
Objective:
To evaluate oesophageal acid exposure, reduction of gastric acid secretion and histology of oesophageal biopsies in infants who clinically do not respond to oral ranitidine.
Patients And Design:
103 infants (mean age 3.3 +/- 1.8 mo) with persisting symptoms of reflux despite administration of ranitidine, prescribed previously by a referring physician, at a mean (SD) dose of 9.4 (+/- 3.3) mg/kg/d for at least 2 wk (mean 30 d), were submitted to a 24-h pH study and oesophageal biopsy (90/103 patients).
Results:
Histological oesophagitis was present in 21/90 (23%). The oesophageal reflux index (RI) was >5% and >10% in 21/103 (20%) and 6/103 (6%) infants, respectively. Gastric pH was >4.0 during <50%, >50%, >75% and >90% of the duration of pH monitoring in 33/103 (32%), 70/103 (68%), 22/103 (21%) and 7/103 (7%), respectively. By simple regression analysis, the dosage of ranitidine correlated with the oesophageal RI (r = 0.21; p = 0.05), but not with the duration of time gastric pH was >4.0 (r = 0.09; p = 0.39). Histological oesophagitis did not correlate with ranitidine dosage, duration of treatment, duration gastric pH was >4.0 and oesophageal reflux index.
Conclusion:
Some infants presenting with symptoms assumed to be GOR and acid related fail to respond to acid suppression with ranitidine, either because they need better acid suppression or because the symptoms are not acid related.
Related Concept Videos
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
